BCM
KZR

Bluefin Capital Management’s Kezar Life Sciences KZR Stock Holding History

Bluefin Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33,610
Closed -$131K – 206
2025
Q3 		$131K Buy
+33,610
New +$138K 0.04% 55

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bluefin Capital Management's KZR Position: Q4 2025 in Review

Bluefin Capital Management sold out of Kezar Life Sciences (KZR) in Q4 2025, closing a stake of 33,610 shares — an estimated $131K sold.

Bluefin Capital Management first reported a position in KZR in Q3 2025 and held it in 1 quarter. The position peaked at $131K in Q3 2025. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2025.

  • Bluefin Capital Management reported no remaining Kezar Life Sciences position as of Q4 2025 after selling out during the quarter.
  • Bluefin Capital Management sold 33,610 Kezar Life Sciences shares in Q4 2025, an estimated $131K.
  • Bluefin Capital Management first reported a position in Kezar Life Sciences in Q3 2025 and held it in 1 quarter.
  • Bluefin Capital Management's Kezar Life Sciences position peaked at $131K in Q3 2025.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2025.

Based on Bluefin Capital Management's 13F filing for Q4 2025, filed 29 Apr 2026.